Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2.
Phenylbutazone (PBZ) toxicosis was induced in 9 ponies to further define the clinical and pathologic changes occurring with this syndrome. Six additional ponies were treated with PBZ and a synthetic prostaglandin E2 to determine the role of prostaglandins in the pathogenesis of PBZ toxicosis. Ponies given only PBZ exhibited CNS depression, anorexia, weight loss, diarrhea, cyanotic mucous membranes, and oral ulcers. Total serum protein concentration gradually decreased during the 10-day treatment period. Marked mucosal atrophy, focal erosions, and ulcers characterized the lesions in the alimentary tract. Ponies given PBZ and prostaglandin E2 remained clinically healthy and did not develop hypoproteinemia or mucosal atrophy. A few erosions were seen, but ulcers were not observed. The results of the present study indicate that mucosal atrophy is a characteristic lesion of PBZ toxicosis. It is also evident that inhibition of prostaglandin synthesis has an important role in the development of this syndrome.
D000818:Animals; D015232:Dinoprostone; D005260:Female; D005767:Gastrointestinal Diseases / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D006734:Horse Diseases / Q000473:pathology* / Q000517:prevention & control; D006736:Horses; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D009336:Necrosis; D010653:Phenylbutazone / Q000506:poisoning*; D011458:Prostaglandins E / Q000627:therapeutic use*; D013577:Syndrome / Q000662:veterinary
D011458:Prostaglandins E; D010653:Phenylbutazone; D015232:Dinoprostone